Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261225 | 0.83 | KMT2A (0.35) | LMNAHTTALDH1A1KMT2AMEN1 | |
| SCHEMBL2586360 | 0.69 | LMNA (0.67) | LMNAHTTALDH1A1USP2POLB | |
| SCHEMBL2579161 | 0.69 | GAA (0.48) | LMNAALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL2587250 | 0.68 | TDP1 (0.41) | LMNANPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2589382 | 0.67 | LMNA (0.53) | LMNAHTTALDH1A1POLBKMT2A | |
| SCHEMBL2585782 | 0.66 | MAPT (0.48) | LMNAHTTALDH1A1POLBKMT2A | |
| SCHEMBL3441394 | 0.65 | KMT2A (0.68) | LMNAHTTALDH1A1USP2POLB | |
| SCHEMBL13902799 | 0.62 | GAA (0.60) | LMNAHTTALDH1A1POLBKMT2A | |
| SCHEMBL3441391 | 0.62 | KMT2A (0.57) | LMNAHTTALDH1A1USP2POLB | |
| SCHEMBL16373639 | 0.62 | CHRM3 (0.49) | LMNAHTTALDH1A1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869053-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | claimed |
| US-8048879-B2 | Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | claimed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| EP-1869053-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105945-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2006-10-12 | — | — | WO | claimed |
| EP-1869053-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-8048879-B2 | Substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1869053-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105945-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | P2RX5, P2RX4, P2RX7 | LMNA 2302/4885HTT 3668/4885ALDH1A1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.